Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Dummer, R ^a   Hauschild, A ^b   Guggenheim, M ^c   Keilholz, U ^d   Pentheroudakis, G ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DABRAFENIB; DACARBAZINE; INTERFERON; IPILIMUMAB; PACLITAXEL; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; TRAMETINIB; VEMURAFENIB; VINDESINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CUTANEOUS MELANOMA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EPILUMINESCENCE MICROSCOPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MELANOMA; METASTASIS; MICROMETASTASIS; PATIENT INFORMATION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS;

EID: 84866600895     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds229     Document Type: Article

References (39)

1. MacKie RM, Bray C, Vestey J et al. Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer 2007; 96(11): 1772-1777.
2. Hollestein LM, van den Akker SA, Nijsten T et al. Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012; 23(2): 524-530.
3. Green AC, Williams GM, Logan V et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29(3): 257-263.
4. Dummer R, Guggenheim M, Arnold AW et al. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2011; 141: w13320.
5. Bono A, Tolomio E, Trincone S et al. Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm. Br J Dermatol 2006; 155(3): 570-573.
6. Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998; 134(1): 103-104.
7. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27(36): 6199-6206.
8. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24(5): 879-897.
9. Schoenewolf NL, Bull C, Belloni B et al. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012; 48: 1842-1852.
10. Hirakawa S, Kodama S, Kunstfeld R et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201(7): 1089-1099.
11. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365 (9460): 687-701.
12. Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355(13): 1307-1317.
13. Eggermont AM, Suciu S, Testori A et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48(2): 218-225.
14. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18(12): 2444-2458.
15. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14(1): 7-17.
16. Mocellin S, Pasquali S, Rossi CR et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102(7): 493-501.
17. Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372(9633): 117-126.
18. Kleeberg UR, Suciu S, Brocker EB et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40(3): 390-402.
19. Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30(3): 316-321.
20. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366(3): 207-215.
21. Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-2383.
22. Farshad A, Burg G, Panizzon R et al. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146(6): 1042-1046.
23. Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. Cancer J 2012; 18(2): 203-207.
24. Burmeister BH, Henderson MA, Ainslie J et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13(6): 589-597.
25. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
26. Ascierto PA, Berking C, Agarwala SS et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 2012; 30 (Suppl); Abstr 8511.
27. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-2516.
28. Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29(21): 2904-2909.
29. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-723.
30. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-2526.
31. von Moos R, Seifert B, Simcock M et al. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 2011; 23(2): 531-536.
32. Kim KB, Sosman JA, Fruehauf JP et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012; 30(1): 34-41.
33. Petrella T, Quirt I, Verma S et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007; 33(5): 484-496.
34. Hamm C, Verma S, Petrella T et al. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 2008; 34(2): 145-156.
35. Titus-Ernstoff L, Perry AE, Spencer SK et al. Multiple primary melanoma: twoyear results from a population-based study. Arch Dermatol 2006; 142(4): 433-438.
36. Turner RM, Bell KJ, Morton RL et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 2011; 29(35): 4641-4646.
37. Bastiaannet E, Wobbes T, Hoekstra OS et al. Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009; 27(28): 4774-4780.
38. Nieweg OE, Kroon BB. The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am 2006; 15(2): 319-330.
39. Beyeler M, Waldispuhl S, Strobel K et al. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2006; 213(3): 187-191.